Skip to content

68 Ga-NODAGA-E[c(RGDγK)]2: Positron Emission Tomography Tracer for Imaging of Myocardial Angiogenesis

68Ga-NODAGA-E[c(RGDγK)]2: a Novel Positron Emission Tomography (PET) Tracer for in Vivo Molecular Imaging of Myocardial Angiogenesis Following Myocardial Infarction

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03445884
Enrollment
42
Registered
2018-02-26
Start date
2018-02-20
Completion date
2020-07-01
Last updated
2020-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myocardial Infarction

Keywords

positron emission tomography, nuclear medicine, prognosis

Brief summary

The aim is to examine the expression of αvβ3 integrin using a novel selective radiotracer in patients with myocardial infarction and investigate if it is a suitable tool for predicting myocardial recovery and thus prognosis.

Detailed description

Ischemic heart disease is worldwide the single most frequent cause of death. The number of patients surviving acute myocardial injury is increasing due to improved acute treatment. However, after the initial repair, the tissue undergoes a remodeling phase to compensate for the damaged area. This re-modeling phase can change the structure end geometry of the heart resulting in lower ejection fraction, leading to cardiac dysfunction, which eventually leads to heart failure. Understanding and ideally modifying the reparative mechanisms following myocardial infarction is increasingly important and may lead to improved outcome. If the heart suffers from ischemia following an acute coronary event, the tissue reacts strongly to the hypoxia. The body will as a compensatory mechanism create new vessel to provide the tissue with oxygen. This is known as the biological process of angiogenesis. This complex process involves different angiogenic and pro-fibrotic transcription factors that initiate the restoration of capillaries by sprouting from the existing endothelial cells in response to hypoxia. Time seem essential to protect and save the myocardium. An early onset of cytokines and growth factors is associated with a decline in cardiomyocytes apoptosis, smaller infarct areas, and decreased ventricular dilation. Therefore, an early induction of angiogenesis seems important for a good prognosis of the patient. Integrin αvβ3 is a transmembrane cell surface receptor that is markedly upregulated in states of angiogenesis. It facilitates migration and proliferation and thereby allowing cells to respond to extracellular environment. Integrin αvβ3 is thus a key player in the angiogenic process. The integrin αvβ3 has a binding site for an RGD peptide (Arg-Gly-Asp motif) and this can be targeted by PET tracers. RGD-based PET tracers have been shown to accumulate at the site of myocardial necrosis in both human and animal studies. The uptake seems to peak a few weeks after the infarction and may correlate to recovery of cardiac function and thus serve as a prognostic marker.

Interventions

200 MBq 68Ga-NODAGA-E\[c(RGDyK)\]2 administered IV.

Sponsors

Rigshospitalet, Denmark
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Age over 50 years Acute myocardial infarction Group: * Verified first-time acute myocardial infarction treated with PCI Control Group: * Previous healthy * No known cardiac disease

Exclusion criteria

* No prior history of acute coronary infarction * No prior history of Heart surgery * Not treated with anti-angiogenic medicine * Subject with pacemaker, cochlear implant or insulin pump * Pregnancy * Lactation * Severe claustrophobia * Severe obesity (weight above 140kg) * If a subject is in the fertile age, a pregnancy test will be use prior to injection to the PET\_tracer * If a subject is having a severe allergic reaction to the PET-tracer, the person will be excluded for the rest of the trial * If the PET-tracer is administered subcutaneous, the person will be excluded for the rest of the trial¨ * Tupe I or II diabetes

Design outcomes

Primary

MeasureTime frameDescription
To evaluate myocardial angiogenesis30-35 daysAnalysing uptake of 68Ga-NODAGA-E\[c(RGDyK)\]2 Positron Emission Tomography in myocardial infarction after PCI

Secondary

MeasureTime frameDescription
Uptake of 68Ga-NODAGA-E[c(RGDyK)]2 and myocardial perfusion30-35 daysQuantitative uptake of 68Ga-NODAGA-E\[c(RGDyK)\]2 and change in myocardial perfusion after PCI using Rubidium 82 Positron Emission Tomography after Percutaneous coronary intervention(PCI)
Uptake of 68Ga-NODAGA-E[c(RGDyK)]2 and functional recovery30-35 daysQuantitative uptake of 68Ga-NODAGA-E\[c(RGDyK)\]2 and functional recovery using Magnetic Resonance after PCI
Uptake of 68Ga-NODAGA-E[c(RGDyK)]2 and viability30-35 daysQuantitative uptake of 68Ga-NODAGA-E\[c(RGDyK)\]2 and viability using Flour-Deoxy-Glucose Positron Emission Tomography after PCI

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026